Voyager Therapeutics, Inc.
$4.23
▼
-0.75%
2026-04-21 10:12:01
www.voyagertherapeutics.com
NMS: VYGR
Explore Voyager Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$252.11 M
Current Price
$4.23
52W High / Low
$5.55 / $2.65
Stock P/E
—
Book Value
$3.32
Dividend Yield
—
ROCE
-58.41%
ROE
-48.29%
Face Value
—
EPS
$-2.04
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
141
Beta
1.38
Debt / Equity
18.61
Current Ratio
7.64
Quick Ratio
7.64
Forward P/E
-2.18
Price / Sales
5.52
Enterprise Value
$62.95 M
EV / EBITDA
-0.51
EV / Revenue
1.56
Rating
Strong Buy
Target Price
$14.89
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | TransCode Therapeutics, Inc. | $8.88 | — | $8.07 M | — | -334.68% | -17.63% | $22.03 / $6.08 | $1.71 |
| 2. | ORIC Pharmaceuticals, Inc. | $10.89 | — | $1.09 B | — | -36.81% | -41.27% | $14.93 / $4.52 | $3.9 |
| 3. | ACADIA Pharmaceuticals Inc. | $22.09 | 9.63 | $3.77 B | — | 8.14% | 39.89% | $28.35 / $14.08 | $7.21 |
| 4. | MiMedx Group, Inc. | $3.25 | 10.44 | $507.35 M | — | 22.95% | 21.61% | $7.99 / $3.31 | $1.73 |
| 5. | ImageneBio, Inc. | $6 | — | $65.99 M | — | -34.18% | -68.91% | $18 / $3.94 | $11.91 |
| 6. | IGC Pharma, Inc. | $0.32 | — | $31.52 M | — | -114.73% | -83.34% | $0.5 / $0.24 | $0.09 |
| 7. | Curis, Inc. | $0.62 | — | $24.33 M | — | -558.61% | 2829.1% | $3.13 / $0.49 | $0.42 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 15.34 M | 13.37 M | 5.2 M | 6.47 M | 6.28 M | — |
| Operating Profit | -29.93 M | -30.59 M | -36.62 M | -34.69 M | -38.3 M | — |
| Net Profit | -27.43 M | -27.89 M | -33.38 M | -31.02 M | -34.49 M | — |
| EPS in Rs | -0.46 | -0.47 | -0.56 | -0.52 | -0.58 | -0.16 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 40.37 M | 80 M | 250.01 M | 40.91 M |
| Operating Profit | -131.84 M | -83.29 M | 122.01 M | -50.84 M |
| Net Profit | -119.72 M | -65 M | 132.33 M | -46.41 M |
| EPS in Rs | -2.01 | -1.09 | 2.22 | -0.78 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 252.28 M | 393.05 M | 351.28 M | 159.36 M |
| Total Liabilities | 56.2 M | 93.29 M | 114.96 M | 100.34 M |
| Equity | 196.08 M | 299.76 M | 236.32 M | 59.02 M |
| Current Assets | 202.69 M | 276.81 M | 319.68 M | 124.5 M |
| Current Liabilities | 26.54 M | 49.79 M | 64.51 M | 72.59 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -132.47 M | -15.31 M | 77.92 M | -12.51 M |
| Investing CF | 125.45 M | -94.86 M | -141.64 M | -7.34 M |
| Financing CF | 0.82 M | 114.02 M | 33.65 M | 1.11 M |
| Free CF | -135.06 M | -18.83 M | 74.66 M | -15 M |
| Capex | -2.6 M | -3.52 M | -3.26 M | -2.49 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -68% | 511.16% | — | — |
| Earnings Growth % | -149.12% | 385.14% | — | — |
| Profit Margin % | -81.25% | 52.93% | -113.45% | — |
| Operating Margin % | -104.11% | 48.8% | -124.27% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -98.19% | 50.58% | -109.14% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.